A study of Medicare data suggests there is substantial variation in the use of antibiotics across regions after adjusting for population characteristics.
Formulary Watch
Latest News
Today's Top Stories
All News
Advertisement
The world of formulary management is changing and organizations must work on education initiatives.
Screening practices for multidrug-resistant organisms (MDROs) in intensive care units (ICUs) vary widely from hospital to hospital, according to a study published in October.
Multiple sclerosis (MS) is a neurologic disorder of chronic inflammation and demyelination of the central nervous system. Several additional agents, including oral products, are now under investigation for the future treatment of MS.
New molecular entity: FDA approved icosapent ethyl (Vascepa, Amarin Pharmaceuticals Ireland Limited), an ethyl ester of eicosapentaenoic acid (EPA), as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia.
Among older adults with atrial fibrillation (AF), persistence with warfarin therapy is generally lower than what has been reported in clinical trials, according study online in Archives of Internal Medicine.
FDA has approved omacetaxine mepesuccinate (Synribo, Teva) to treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease. An estimated 5,430 people will be diagnosed with CML in 2012, according to the National Institutes of Health. Synribo is intended to be used in patients whose cancer progressed after treatment with at least 2 drugs from a class called tyrosine kinase inhibitors (TKIs), also used to treat CML.
Long-term treatment of folic acid and vitamin B6 and vitamin12 had no statistically significant effect on colorectal adenoma among women who were at high risk for cardiovascular disease, according to recent study published in the Journal of the National Cancer Institute.
Half of the 3.2 billion prescriptions dispensed annually are not taken as prescribed. Pharmacy benefit leaders must reconsider the financial context of medication adherence and medication possession, according to industry leaders presenting at an online seminar for the Pharmacy Benefit Management Institute in October.
Cardiac transplant patients may be at a higher risk for hospitalization due to drug-related problems than the general population, according to the results from a single cardiac transplant center, published the October issue of The Annals of Pharmacotherapy.
Advertisement
The Advisory Committee for Immunization Practices (ACIP) voted to recommend the use of Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine (MenHibrix, GlaxoSmithKline) in infants at increased risk for bacterial meningitis.
Numerous health and safety violations related to the practice of pharmacy at the New England Compounding Center (NECC), Framingham, Mass. have been documented by investigators of the Massachusetts Department of Public Health (DPH), according to Madeleine Biondolillo, MD, in a press conference Oct. 23
Three investigational drugs will be studied in a worldwide clinical trial to determine whether they can prevent Alzheimer’s disease. In people with inherited mutations that cause early-onset Alzheimer’s, the study will seek to identify whether the drugs can improve Alzheimer’s disease biomarkers and prevent the loss of cognitive function.
FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.
meningitis, steroids, FDA, CDC, compounding
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has updated its recommendations for pneumococcal vaccine in high-risk adults.
Screening patients who are at high risk for diabetes does not reduce their all-cause, cardiovascular, or diabetes-related mortality within 10 years, according to a study published October 4 in The Lancet.
Women who take HRT for 10 years following menopause have a significantly reduced risk of mortality, heart failure, and heart attack without any increased risk of cancer, DVT, or stroke, a Danish study published on bmj.com showed.
FDA has warned patients of thrombotic thrombocytopenic purpura (TTP), a serious blood disorder, resulting from misuse of oxymorphone hydrochloride extended-release tablet (Opana ER, Endo).
FDA and the Centers for Disease Control and Prevention (CDC) confirm that the fungus Exserohilum rostratum contaminated 1 of the 3 implicated lots of preservative-free methylprednisolone acetate (80 mg/mL) from the New England Compounding Center (NECC), which the company recalled September 26.
FDA has expanded the approved indication for tocilizumab (Actemra, Genentech) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs (DMARDs).
New evidence suggests that statins generate large survival and health benefits at the population level and shows that the social value of the survival gains are large and go predominantly to consumers, according to a study published in the October issue of Health Affairs.
Patients with breakthrough cancer pain (BTCP) may want to consider intranasal fentanyl spray over oral agents to treat their breakthrough pain because of improved onset of analgesia and avoidance of nausea and vomiting, according to a report published online for The Annals of Pharmacotherapy.
Patients who experience a warfarin-associated gastrointestinal tract bleeding event should resume anticoagulation therapy during the 90 days following the event to decrease the risk of thrombosis and death, according to a study published online in the Archives of Internal Medicine.
Use of concurrent sedating agents provides rapid sedation and reduces the need for resedation in acutely agitated patients, according to clinical trial results published online in the Annals of Emergency Medicine.
FDA has approved paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (Abraxane, Celgene) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
HS patients on biosimilar adalimumab lose response faster than those on the original drug
3
New drug class shows promise for geographic atrophy
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5
